Preparation, characterization, and biological evaluation of a streptavidin-chimeric T84.66 conjugate for antibody pretargeting

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 5, 2007, Pages 654-664

  Jia, Fang ^a   Shelton, Tiffani D ^b   Lewis, Michael R ^a,b,c,d  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

Biotin; Carcinoembryonic antigen; Chimeric T84.66 antibody; Pretargeting; Streptavidin

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BIOTIN; CARBOXYLIC ACID DERIVATIVE; CARCINOEMBRYONIC ANTIBODY; DITHIOTHREITOL; IMINE; MALEIMIDE DERIVATIVE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY T84.66; STREPTAVIDIN; SUCCINIMIDYL 4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLATE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL REACTION; CHIMERA; CONJUGATE; CONJUGATION; CONTROLLED STUDY; DISULFIDE BOND; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REACTION ANALYSIS; XENOGRAFT;

ANIMALS; BIOTIN; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; HUMANS; IMMUNOTOXINS; INDIUM RADIOISOTOPES; MALEIMIDES; MICE; MICE, NUDE; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; STREPTAVIDIN; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35848966792     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.343-S     Document Type: Article

References (40)

1. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316.
2. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453.
3. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci 2000;97:1802.
4. Hylarides MD, Mallett RW, Meyer DL. A robust method for the preparation and purification of antibody/streptavidin conjugates. Bioconjugate Chem 2001;12:421.
5. Weber PC, Ohlendorf DH, Wnndeloski JJ, et al. Structural origins of high-affinity biotin binding to streptavidin. Science 1989;243:85.
6. Foulon CF, Bigner DD, Zalutsky MR. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. Bioconjugate Chem 1999;10:867.
7. 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol 2004;31:213.
8. Sharkey RM, Karacay H, Griffiths GL, et al. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer: Studies in a human colon cancer xenograft model. Bioconjugate Chem 1997;8:595.
9. Karacay H, Sharkey RM, Govindan SV, et al. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer: Reagent development. Bioconjugate Chem 1997;8:585.
10. Cremonesi M, Ferrari M, Chinol M, et al. Three-step radioimmunotherapy with yttrium-90 biotin: Dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med 1999;26:110.
11. Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA X Anti-DTPA-Indium bispecific antibody. J Nucl Med 1998;39:1172.
12. 90Y radioimmunotherapy. Cancer Res 1994;54:5937.
13. 99mTc-labeled morpholino, a DNA analog. J Nucl Med 2002;43:384.
14. Wang Y, Chang F, Zhang Y, et al. Pretargeting with amplification using polymeric peptide nucleic acid. Bioconjugate Chem 2001;12:807.
15. Gold P, Freedman SO. Demonstration of tumor-specific antigens in buman colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med 1965;121:439.
16. Esteban JM, Felder B, Ahn C, et al. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer 1994;74:1575.
17. Robbins PF, Eggensperger D, Qi CF, et al. Definition of the expression of the human carcinoembryonic antigen and nonspecific cross-reacting antigen in human breast and lung carcinomas. Int J Cancer 1993;53:892.
18. Neville AM, Laurence DJR. Report on the workshop on carcinoembryonic antigen (CEA): The present position and proposals for future investigation. Int J Cancer 1974;14:1.
19. Seppala M, Pihko H, Ruoslahti E. Carcinoembryonic antigen and a fetoprotein in malignant tumors of the female genital tract. Cancer (Phila) 1975;33:1377.
20. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res (Suppl). 1995;55:S5935.
21. 111In-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res 1986;46:6494.
22. Morton BA, O'Connor-Tressel M, Beatty BG, et al. Artifactual CEA elevation due to human anti-mouse antibodies. Arch Surg 1988;10:1242.
23. Neumaier M, Shiverly L, Chen FS, et al. Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and chinese hamster ovary cells. Cancer Res 1990;50:2128.
24. Wong JY, Thomas GE, Yamauchi D, et al. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody. J Nucl Med 1997;38:1951.
25. 90Yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial. Cancer Res 1995;55:5929S.
26. 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 2000;6:3855.
27. 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003;9:5842.
28. 90Y-labeled DOTA and maleimidocysteineamido- DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: Comparison of stable and chemically labile linker systems. Bioconjugate Chem 1998;9:87.
29. Bryan JN, Jia F, Mohsin H, et al. Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. Nucl Med Biol 2005;32:851.
30. 90Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm 2006;21:88.
31. Axworthy DB, Theodore LJ, Gustavson LM, et al. Biotinidase-resistant biotin-DOTA conjugates: U.S. Patent 5,608,060. 1997.
32. Hofmann K, Wood SW, Brinton CC, et al. Iminobiotin affinity columns and their application to retrieval of streptavidin. Proc Natl Acad Sci 1980;77:4666.
33. Hamblett K, Press O, Meyer D, et al. Role of biotinbinding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma. Bioconjugate Chem 2005;16:131.
34. Klumb L, Chu V, Stayton PS. Energetic roles of hydrogen bonds at the uriedo oxygen binding pocket streptavidin-biotin complex. Biochemistry 1998;37:7657.
35. Mock DM, DuBois DB. A sequential, solid-phase assay for biotin in physiologic fluides that correclates with expected biotin status. Anal Biochem 1986;153:272.
36. Baker H. Assessment of biotin status: Clinical implications. Ann NY Acad Sci 1985;447:129.
37. 64Cu for tumor imaging and therapy. J Nucl Med 2003;44:1284.
38. Shively JE, Beatty JD. CEA-related antigens: Molecular biology and clinical significance. Crit Rev Oncol Hematol 1985;2:355.
39. Graves SS, Dearstyne E, Lin Y, et al. Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res 2003;9:3712.
40. 177Lu. Bioconjugate Chem 2006;17:485.